Bryant et al. created adaptamers, 120 bp RNA sequences which act as regulatory elements of mRNAs so that translation only occurs in the presence of a small molecule inducer (tetracycline or doxycycline). They work by recruiting endogenous adenosine deaminases to edit out a stop codon only when the inducer stabilizes a stem loop structure. A very clever design with lots of promise for gene therapy!

Bryant et al. develop adaptamers, compact RNA switches that use FDA-approved drugs to control gene expression by co-opting endogenous RNA-editing machinery rather than relying on foreign proteins. In mice, this approach safely tuned a metabolic hormone to reverse obesity, pointing to a simpler path toward programmable, drug-controlled gene therapies.